M
Masahiro Ando
Researcher at Kagoshima University
Publications - 53
Citations - 5832
Masahiro Ando is an academic researcher from Kagoshima University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 29 publications receiving 5204 citations. Previous affiliations of Masahiro Ando include Nippon Medical School.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue,Kunihiko Kobayashi,Kazuhiro Usui,Makoto Maemondo,Shoji Okinaga,Iwao Mikami,Masahiro Ando,Koichi Yamazaki,Yasuo Saijo,Akihiko Gemma,Hitoshi Miyazawa,Tomoaki Tanaka,Kenji Ikebuchi,Toshihiro Nukiwa,Satoshi Morita,Koichi Hagiwara +15 more
TL;DR: This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib, and examination of EGFR mutations as a biomarker is recommended in this patient population.
Journal ArticleDOI
Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy
Yuji Minegishi,Kiyoshi Takenaka,Hideki Mizutani,Junko Sudoh,Rintaro Noro,Tetsuya Okano,Arata Azuma,Akinobu Yoshimura,Masahiro Ando,Eitaka Tsuboi,Shoji Kudoh,Akihiko Gemma +11 more
TL;DR: There was no evidence that anticancer treatment, including chemotherapy, should be avoided in LC with IIP, and a prospective clinical study should be performed to evaluate various treatment modalities in a larger patient population.
Journal ArticleDOI
Genetic profile and onset features of 1005 patients with Charcot-Marie-Tooth disease in Japan
Akiko Yoshimura,Junhui Yuan,Akihiro Hashiguchi,Masahiro Ando,Yujiro Higuchi,Tomonori Nakamura,Yuji Okamoto,Masanori Nakagawa,Hiroshi Takashima +8 more
TL;DR: First decade of life was found as the most common disease onset period, and early-onset CMT cases were most likely to receive a molecular diagnosis, and geographical distribution analysis indicated distinctive genetic spectrums in different regions of Japan.
Journal ArticleDOI
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
Kazuhiro Kitamura,Kaoru Kubota,Masahiro Ando,Satoshi Takahashi,Nobuhiko Nishijima,Teppei Sugano,Masaru Toyokawa,Koji Miwa,Seiji Kosaihira,Rintaro Noro,Yuji Minegishi,Masahiro Seike,Akinobu Yoshimura,Akihiko Gemma +13 more
TL;DR: This is the first study to report that bevacizumab plus chemotherapy is highly effective for the management of MPE in non-squamous NSCLC patients, especially regarding the control of pleural effusions.